RxDoctor Payments Data

James Schrenker, MD

Family Medicine · Bristol, TNNPI 1710981535

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $79 of the $102 with a category attached, or 77.3%. 4 manufacturers reported payments, led by Lilly USA, LLC at 40.5% of the total. 2022 is the largest year on record at $49, 3.0 times the $16 reported in 2020. That places this record below the midpoint for family medicine clinicians in TN, where the typical reported total is $470.

$102in general payments, 2019–2025

Across 6 payments — averaging $16.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$41
  • AstraZeneca$23
  • Abbott$21
  • Novo Nordisk$16

What the payments were for

  • Food & beverage$7977%
  • Education$2323%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC2$41
AstraZeneca2$23
Abbott1$21
Novo Nordisk1$16

How this compares

$102 in reported general payments places this provider in the 25th percentile of 2,087 family medicine providers in Tennessee.

See all family medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$220,324
Medicare patients
529
Services billed
5,986

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban132$132,404
TrulicityDulaglutide73$119,067
MounjaroTirzepatide80$115,095
JardianceEmpagliflozin49$74,989
OzempicSemaglutide16$25,941
XareltoRivaroxaban17$18,542
ProgesteroneProgesterone, Micronized333$15,185
SymbicortBudesonide/Formoterol Fumarate30$10,872
MyrbetriqMirabegron16$9,040
Lantus SolostarInsulin Glargine,hum.Rec.Anlog63$7,515
TradjentaLinagliptin12$6,342
BrilintaTicagrelor12$6,301
Levothyroxine Sodium651$5,341
SynthroidLevothyroxine Sodium67$4,961
Losartan Potassium419$4,834

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$41$234,162153 claims
Novo NordiskOzempic$16$25,94116 claims
AstraZenecaSymbicort, Brilinta$23$17,17242 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 2,087 family medicine providers in Tennessee.

Other family medicine in Bristol

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →